These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 9164233)

  • 1. Survival benefit in melanoma.
    Williams MV; De Takats P; Parmar M
    J Clin Oncol; 1997 May; 15(5):2172. PubMed ID: 9164233
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant IFN alpha2 therapy of melanoma.
    Kirkwood JM
    Lancet; 1998 Jun; 351(9120):1901-3. PubMed ID: 9654253
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant interferon alfa-2b for high-risk melanoma.
    Retsas S
    J Clin Oncol; 1996 Jun; 14(6):1968-9. PubMed ID: 8656272
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjuvant interferon in the treatment of melanoma.
    Middleton MR
    Br J Cancer; 1999 Aug; 80(11):1679-80. PubMed ID: 10468281
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant therapy of melanoma.
    Retsas S
    Lancet; 1998 Aug; 352(9129):737-8. PubMed ID: 9729017
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant high-dose interferon revisited.
    Sondak VK; Flaherty LE
    Cancer J; 2000; 6(3):132-4. PubMed ID: 10882326
    [No Abstract]   [Full Text] [Related]  

  • 7. Sorting the hype from the facts in melanoma.
    Autier P; Boyle P; Doré JF
    Lancet; 1998 Aug; 352(9129):738-9. PubMed ID: 9729018
    [No Abstract]   [Full Text] [Related]  

  • 8. [High-dose interferon-alpha and adjuvant treatment of melanoma with poor prognosis: requiem for a drug marketing license?].
    Saiag P
    Ann Dermatol Venereol; 1999 Mar; 126(3):211-3. PubMed ID: 10394432
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant interferon for stage II melanoma.
    Haluska FG
    J Clin Oncol; 1998 Sep; 16(9):3205-6. PubMed ID: 9738597
    [No Abstract]   [Full Text] [Related]  

  • 10. Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: trade-offs between completeness, simplicity and clarity.
    Hillner BE; Kirkwood JM
    Eur J Cancer; 1997 Aug; 33(9):1345-6. PubMed ID: 9337671
    [No Abstract]   [Full Text] [Related]  

  • 11. Interferon for melanoma: another application of immunopharmacology.
    Nauman C
    JAMA; 1998 Apr 22-29; 279(16):1263. PubMed ID: 9565004
    [No Abstract]   [Full Text] [Related]  

  • 12. [Melanoma: a new interferon is coming ... handle with care!].
    Négrier S
    Bull Cancer; 1997 Apr; 84(4):435-7. PubMed ID: 9238171
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dose adjuvant interferon therapy for melanoma.
    Licata AG
    Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [To outwit melanoma with its own tricks].
    Bischoff A
    MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
    [No Abstract]   [Full Text] [Related]  

  • 15. The adjuvant treatment of malignant melanoma.
    Reintgen D; Kirkwood J
    J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant melanoma.
    Johnson DM; Hayat SQ; Burton GV
    J Rheumatol; 1999 Apr; 26(4):1009-10. PubMed ID: 10229440
    [No Abstract]   [Full Text] [Related]  

  • 17. [Interferon-alpha can improve the prognosis in high-risk melanoma. Combination of surgery, cytostatics and natural IFN-alpha doubled the survival rate].
    Strannegärd O; Thorén FB; Lundgren E
    Lakartidningen; 2008 Feb 6-12; 105(6):358-61. PubMed ID: 18380352
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant therapy for melanoma: How should we respond to high-dose interferon?
    de Takats PG; Williams MV; Hawkins R
    Br J Cancer; 1998 Apr; 77(8):1287-93. PubMed ID: 9579835
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma.
    Lohmann CP; Kroher G; Bogenrieder T; Spiegel D; Preuner J
    Lancet; 1999 Apr; 353(9161):1326. PubMed ID: 10218534
    [No Abstract]   [Full Text] [Related]  

  • 20. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
    Keilholz U; Stoter G; Punt CJ; Scheibenbogen C; Lejeune F; Eggermont AM
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S22-8. PubMed ID: 9457389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.